CORTECHS LABS INC

Their core work

CorTechs Labs is a San Diego-based medical technology SME that develops computational tools for neurological and psychiatric assessment. In European research, they contribute quantitative analytics capabilities to large-scale mental health studies, supporting the development of risk prediction models that integrate genetic, clinical, and lifestyle data for patients with severe mental illness. Their work spans cardiovascular comorbidity prediction in psychiatric populations and pharmacogenomic stratification — determining which psychiatric drugs are most likely to benefit or harm specific patients based on their genetic profiles. They bring software and data science expertise that allows large multi-country consortia to extract actionable clinical intelligence from registries, biobanks, and eHealth records.

What they specialise in

How they've shifted over time

Their first H2020 project (CoMorMent, 2020) focused on the physical health consequences of psychiatric illness — specifically predicting cardiovascular disease in people with severe mental illness using genetic risk scores, lifestyle factors, and large biobank data. By their second project (REALMENT, 2021), the focus had shifted inward to the psychiatric conditions themselves: schizophrenia, bipolar disorder, and major depressive disorder — and specifically to how genetic variation affects drug response and adverse effects. The trajectory moves from disease co-occurrence modeling toward pharmacogenomic precision medicine, suggesting the organization is deepening its capabilities in genotype-driven clinical decision support.

CorTechs Labs appears to be moving toward clinical pharmacogenomics applications in psychiatry — a high-value niche where their computational tools could directly inform prescribing decisions for patients with treatment-resistant mental illness.

How they like to work

CorTechs Labs has participated exclusively as a non-leading partner across both projects, suggesting they join consortia as a specialist contributor rather than a project driver. Their presence in consortia with 18 distinct partners across 10 countries implies they are valued for a specific technical capability that European partners seek from outside the EU. As a US-based SME in H2020 projects — where third-country participation requires deliberate inclusion — their repeated recruitment signals that their tools or expertise fill a gap that consortium partners cannot source locally.

CorTechs Labs has built connections with 18 consortium partners across 10 countries through just two projects, indicating they enter large, multi-national health research consortia rather than small bilateral collaborations. As a US company participating in European Health pillar projects, their network spans both sides of the Atlantic.

What sets them apart

CorTechs Labs is a rare example of a US commercial SME embedded in European psychiatric research consortia — their inclusion as a non-EU partner in two consecutive Horizon 2020 health projects implies they hold specialized software or analytics capabilities that European academic and clinical partners specifically recruited them for. Their combination of psychiatric risk modeling and pharmacogenomics tools positions them at the intersection of digital health technology and clinical psychiatry, a crossover that few companies in either sector fully occupy. For consortium builders, they represent a direct channel to US-based neurotechnology expertise with demonstrated experience in EU research compliance and multi-country data governance.

Highlights from their portfolio

• CoMorMent
  The larger of their two projects (EUR 264,571) and the entry point into EU research, tackling the clinically important but under-researched link between psychiatric illness and cardiovascular disease risk through genetic decoding.
• REALMENT
  Marks a strategic pivot toward pharmacogenomics — using real-world big data from eHealth systems and biobanks to predict individual drug response and adverse effects in patients with schizophrenia, bipolar disorder, and MDD.